The role of bispecific antibodies in the treatment landscape for R/R ...

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, provides insight into the role ...

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, provides insight into the role ...

The Role of Bispecific Antibodies in Relapsed Refractory Multiple ...

Bispecific antibodies (BsAbs) can bind simultaneously to the CD3 T-cell receptor and tumor antigen of myeloma cells, causing cell lysis. This ...

The role of bispecific antibodies in the treatment of R/R large B-cell ...

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, shares some insights into the role of ...

The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell ...

... treatment landscape of diffuse large B-cell lymphoma (DLBCL) over the last two decades ... R/R DLBCL ineligible for curative therapy.

Dr Awan on the Evolving Role of Bispecific Antibodies Treatment in ...

Initially introduced for patients in the third-line setting or those who were ineligible for CAR T-cell therapy, bispecific antibodies have ...

Bispecific antibodies in the treatment of multiple myeloma - Nature

Bispecific antibodies are dual antigen targeting constructs that engage the T cells to plasma cells through various target antigens.

Advancements in R/R Lymphoma: Bispecific Antibodies in Focus

We have bispecific monoclonal antibodies, which is mosunetuzumab that has been approved by FDA and by EMA, and it's also in the process of being ...

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B ...

Diffuse large B-cell lymphoma is an aggressive and biologically heterogeneous disease. R-CHOP is the standard first line therapy and cures more ...

Bispecific antibodies for the treatment of B-cell lymphoma

Blinatumomab was the first BsAb to enter the clinical arena. In a phase 1 trial in selected patients with relapsed or refractory (R/R) B-NHL, it ...

An overview of bispecifics in R/R myeloma and their integration into ...

The anti-BCMA antibodies teclistamab and elranatamab result in a high overall response rate (ORR), with many of these responses being complete ...

The important role of bispecific antibodies in the future ... - YouTube

The role of bispecific antibodies in the treatment landscape for R/R DLBCL. VJHemOnc – Video Journal of Hematology & HemOnc•179 views · 2:52.

Bispecific antibodies for the treatment of relapsed/refractory multiple ...

However, the advent of novel immunotherapies such as bispecific antibodies are rapidly changing the treatment landscape and improving the survival outcomes of ...

Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for ...

Bispecific antibodies: advancing precision oncology: Trends in Cancer

Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of ...

Bispecific antibodies: advancing precision oncology - ScienceDirect

Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of resistance to ...

The landscape of bispecific T cell engager in cancer treatment

Blinatumomab has been approved by FDA for the treatment of both children and adults with R/R B-ALL and gained accelerated approval to treat ...

Bispecific Antibody Use in Patients With Lymphoma and Multiple ...

In patients with RR-NHL, neutropenia is described in 20%-40%, anemia in 15%-45%, and thrombocytopenia in 10%-25%. ... Most of these cytopenias are ...

A pivotal decade for bispecific antibodies? - Taylor & Francis Online

Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal. Nevertheless, ...

Sequencing of cellular therapy and bispecific antibodies for the ...

In the past 2 years, two CD20 x CD3 bispecific antibodies were approved by the Food and Drug Administration for the treatment of R/R DLBCL after ...